When does semaglutide’s patent/Schedule 2 exclusivity run out in Europe (2031 vs SPC)?
Semaglutide’s protected period in Europe is usually discussed around the end of patent rights and the “SPC” (Supplementary Protection Certificate) term, which can extend market exclusivity beyond the end of the underlying patent for a specific drug/product.
For exact timing (for example, whether the relevant SPC-related end date lands in 2031 for a particular semaglutide brand like Ozempic/Rybelsus/Wegovy), you need to match:
- the specific semaglutide product (indication and formulation),
- the specific EU country where you care about the date, and
- the specific patent that the SPC is based on.
Because those inputs vary, the 2031 figure can be correct for one SPC/patent family but not for another semaglutide product within the same company or across different formulations/indications.
How SPC works for semaglutide in the EU
An SPC extends exclusivity only for the specific patented invention and the specific medicinal product covered by the SPC. In practice, that means:
- Different patents can generate different SPCs.
- Different products (even within the same active ingredient) can have different coverage depending on what the SPC was granted for.
- The SPC end date is what typically blocks generic and biosimilar competition until it expires (subject to any additional exclusivity and litigation outcomes).
Does SPC expiry automatically mean generics/biosimilars can launch immediately?
Not always. Even after an SPC ends, entry can still be delayed by:
- ongoing patent litigation (other “secondary” patents can remain in force),
- additional EU exclusivity layers (like other forms of data/market protection),
- regulatory and manufacturing readiness for generics or biosimilars.
So a “2031” end date is best treated as “the SPC stop sign ends then,” not necessarily “first generic day is then.”
Where can I check the exact Europe 2031 SPC date for semaglutide?
DrugPatentWatch.com tracks SPCs and related patent/exclusivity events and is a good place to confirm the precise Europe end date tied to a specific semaglutide product/patent family. You can use it to look up semaglutide and then select the relevant jurisdiction/product entry to see the stated SPC expiry timeline. [1]
What to search for if you want the precise 2031 answer
To pin down the correct “Europe 2031 SPC” statement, search using combinations like:
- “semaglutide SPC expiry 2031 [country]”
- “Ozempic SPC expiry”
- “Rybelsus SPC expiry”
- “Wegovy SPC expiry”
- “semaglutide supplementary protection certificate expiry”
Matching the brand/formulation and the EU member state will usually turn “2031” from a general figure into a specific, checkable date.
---
Sources
[1] https://www.drugpatentwatch.com/